Sinopharm Capital

Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation that specializes in medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. It seeks to invest in China. Sinopharm Capital was founded in June 2012 and is based in Shanghai, China.

Wu, Aimin

President

41 past transactions

Artivila Therapeutics

Seed Round in 2022
Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform, providing first-in-class new molecules consistently and efficiently. Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China.

Metanovas Biotech

Seed Round in 2022
Metanovas develops nutraceutical and cosmeceutical products with revolutionary AI technology. The company's product pipeline includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, providing patients and consumers with better goods. Metanovas alters how science and AI are used to generate health products.

CytoNiche

Series B in 2022
CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated and intelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products.

Xishan

Series D in 2021
Xishan produces and sells minimally invasive surgical devices. They also offer speculums, energy surgery equipment, and more. Their products are utilized in neurosurgery, ENT, orthopedics, breast surgery, and other clinical areas.

Sumgen Biotech

Venture Round in 2021
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CART antibodies. .

Longhui Medical

Series B in 2021
Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service.

Sepax Technologies

Series D in 2021
Sepax Technologie is a biotechnology firm that offers ion exchange, hydrophobic interaction, and method development services.
Shanghai Ouyi Biomedical Technology Co., Ltd., established in 2009, is a high-tech enterprise of multi-omics testing services with "specialization, specialization and new". It has built a multi-omics testing platform covering nucleic acid, protein, and metabolism. Big data analysis platform combined with multi-omics. For pharmaceutical, food and daily chemical companies; life sciences, medicine and clinical research fields, provide drug target discovery, pharmacological efficacy and safety evaluation, disease molecular marker screening, pathogenic bacteria and drug resistance traceability, life development research and Multi-level and multi-omics testing services and solutions for disease occurrence and development research.

Brise Pharma

Angel Round in 2021
Brise Pharma operates in the scientific research and technical service industry.

Geneus

Series B in 2021
Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Yikon Genomics

Series D in 2021
Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life.

FutureGen

Series B in 2021
FutureGen is a biopharmaceutical company that develops innovative biologics. The company works in the fields of immunology and cancer, concentrating on the creation and commercialization of novel biologics. The STEP (Structure-based Targeted Evolution Platform) from FutureGen is a cutting-edge screening platform designed specifically for protein drug screening. It integrates several technologies to quickly screen and produce the best antibodies. FutureGen has experience in medication development, clinical research, CMC, and quality in the business world.

Kira Pharmaceuticals

Venture Round in 2020
Kira Pharmaceuticals their treatment gives pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases.

Dingdang Kuaiyao

Series B in 2020
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

GenFleet Therapeutics

Series B in 2020
GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

ArteryFlow

Series A in 2019
ArteryFlow is an intelligent diagnostic system developer, which combines computational fluid dynamics, 3D medical image reconstruction, big data and artificial intelligence technology, and provides intelligent diagnosis, image-assisted diagnosis, technical training and guidance to users in scientific research institutions, hospitals, clinics and other fields by using technical means such as automated grid generation, virtual therapy, accurate diagnosis, etc

Baicare

Series B in 2019
Baicare aims to improve the level of clinical microbiological testing and promote the rational use of antibiotics. Based on microfluidic chips and gene detection technology, it provides intelligent automated nucleic acid detection products for clinical hospitals. One chip can quickly and accurately detect pathogenic bacteria. And its drug resistance, to provide doctors with effective treatment programs, reduce patient suffering, and significantly save social medical costs. Baicare has developed rapidly and won a number of financial support such as the “13th Five-Year National Science and Technology Major Project” . It has applied for more than 20 related patents and was awarded “National High-Tech Enterprise”. Baikangxin has also been favored by medical experts and the capital market.

Synyi

Series C in 2019
The Senyi team is composed of elites from well-known universities and well-known companies at home and abroad. It integrates experts in areas such as artificial intelligence, medicine, medical informatics, and medical informationization. The core team's technical achievements have been applied to a number of national and municipal projects. He has published more than 20 papers in international top journals and has spoken at top international medical conferences.

Novena Global Healthcare Group

Private Equity Round in 2019
Novena Global Lifecare is a unique integrated Healthcare platform.
Suzhou And Science Technology Development is a surgical medical device developer, mainly for the operating room, emergency room and treatment room. The products include “AND” brand minimally invasive vertebroplasty system, medical vacuum drainage system, high-pressure pulse irrigation system, Single-use irrigators, external fixation systems, and DC orthopedic drill chainsaws.

Dingdang Kuaiyao

Series C in 2019
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

HealthCare Biotech

Series B in 2019
Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.

Skynor Medical

Series A in 2018
Skynor Medical is a supplier of medical equipment. Their products include peripheral vascular stent systems, distal access catheters, microcatheters, thrombectomy devices, and balloon dilatation catheters.

Virogin Biotech

Venture Round in 2018
Virogin Biotech Ltd. ("Virogin") was founded in 2015, with the headquarters located in Vancouver, Canada. They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.

GenFleet Therapeutics

Series A in 2018
GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

Dr.Yu Pediatrics Clinics

Series A in 2018
Dr.Yu Pediatrics Clinics is a Healthcare company.

LinaTech

Seed Round in 2018
LinaTech engages in research and development, production, sales, and service of radiotherapy equipment products. They build a product line from spare parts to complete machines. They commit to bringing accurate and effective treatments to patients around the world.

Eccogene

Series A in 2018
Eccogene is a clinical stage biopharmaceutical company that provides therapeutic solutions to address unmet medical needs. They offer services in the discovery and development of translational medicine in metabolic and immune-related diseases.

Topsuper

Angel Round in 2018
Topsuper specializes in R&D, production and sales of medical equipment.

Ansun BioPharma

Series A in 2018
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Eyebright

Series C in 2018
Eyebright involves the protection and caring of human beings’ eyes and vision health. The company develops medical products such as surgical implants, surgical instruments, equipment, optometric lenses, eye drops, and other related medical devices for the treatment of cataracts, glaucoma, refractive errors, and other ophthalmic diseases.

LYNK Pharmaceuticals

Angel Round in 2018
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

Ancare Medical

Seed Round in 2018
Ancare solve the psychological distress by treating both symptoms and root causes. They are helping each visitor solve both the symptoms and the root causes of psychological distress and have a happy life.

Virtual Incision

Series B in 2017
Virtual Incision is a pioneer in in vivo mini-robot surgery, focusing on minimally-invasive procedures for colorectal conditions, including cancer, diverticulitis, and Crohn's disease. With nearly 400,000 colectomies performed annually in the U.S., the company aims to transform this landscape, as two-thirds of these surgeries are still done through large incisions. By introducing a mini-robot inserted via a small umbilical incision, Virtual Incision allows surgeons to manipulate the robot arms from a nearby console, facilitating the use of familiar laparoscopic tools and enhancing surgical capabilities. This innovative approach not only simplifies the surgical process but also seeks to improve clinical outcomes and reduce healthcare costs. With over 60 patents and extensive preclinical testing, Virtual Incision is currently pursuing $15 million in Series B financing to advance its technology toward First-in-Man trials and regulatory submissions.

Semma Therapeutics

Series B in 2017
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Abbisko Therapeutics

Series A in 2017
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.

JoyMed Technology

Seed Round in 2016
JoyMed Technology offers medical device product research and development, registration, manufacturing services, and complete medical device product solutions. The company ontinues to develop innovative and dependable technology, as well as high-quality medical device products, and the global market expands. Customers can reduce time to market by utilizing a flexible cooperation mode, quick response, an optimized product design process, and team design experience. It aims to become a trustworthy partner for domestic and foreign medical device companies, as well as to assist domestic and foreign small and medium-sized businesses in dealing with the challenges of the medical product device market. , in order to accelerate mutual growth with customers.

InventisBio

Series A in 2016
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

FHNED

Series A in 2015
FHNED is a company that offers a range of seawater desalination products and services. Their products include sea dew sea hydrogen water, hai dew still sparkling water, marine ecological water, compound fruit and vegetable juice drink, and more. The company's contact modes are mail, phone, and physical address.

Anbiping

Series A in 2013
Anbiping is a number of reagents and supporting devices have indeed been independently created by Anbiping, which focuses on tumour screening and correct diagnosis. Pathology is the main application department. It has been established that product lines for liquid-based cytology, polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization can be used to screen for and diagnose tumors based on everything from cell morphology to protein expression.

ZC511.com

Angel Round in 2012
ZC511.com information is gathered, categories and services are provided, and the information flow, commodity flow, financial flow, and distribution flow are created by the pharmaceutical industry chain. Chinese patent medicines, chemical drug preparations, chemical raw materials, antibiotic preparations, antibiotic raw materials, biochemical medications, biological products, chinese medicinal materials, chinese herbal components, and other items are all part of their business.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.